Headquartered in Denver, CO Fiscal year ends December NYSE: DVA davita.com
DaVita Inc. is a major kidney care services company that provides dialysis treatment to patients with end-stage renal disease (ESRD) and chronic kidney disease. The company operates 3,266 outpatient dialysis centers across 15 countries, including 2,671 centers in the United States and 595 internationally, serving approximately 298,500 patients. Beyond traditional in-center dialysis, DaVita operates an Integrated Kidney Care (IKC) platform that manages risk-based and value-based care arrangements covering approximately 64,900 patients representing roughly $5.8 billion in annualized medical spend. The company's business model centers on recurring dialysis treatments, typically provided three times per week, with revenue derived from a mix of commercial insurance, Medicare, Medicaid, and other government programs. DaVita also engages in home-based dialysis services and is exploring innovations in kidney care including middle molecule toxin clearance technologies. Updated
Warren Buffett stepped down as Berkshire Hathaway's CEO at the start of 2026, handing the reins to Greg Abel. His legacy as an investor, however, remains as relevant as ever. For long-term…
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
Warren Buffett is the world’s greatest investor. Since becoming chairman of Berkshire Hathaway (NYSE:BRK-A | BRK-A Price Prediction)(NYSE:BRK-B) in the mid-1960’s, he has generated annual average returns of almost 20%, or nearly…
24/7 Insights Warren Buffett’s best-performing stocks include new and legacy corporations in construction, banking, and investments. Most experts recommend investors hold these stocks if they already own them, or cautiously buy more.…
In August, Warren Buffett’s Berkshire Hathaway (NYSE: BRK-B | BRK-B Price Prediction) became the first non-tech U.S. company to reach a $1 trillion market cap. The Omaha-based conglomerate’s shares have surged more…
Warren Buffett has obliterated the market’s returns since becoming CEO of Berkshire Hathaway (NYSE:BRK-A | BRK-A Price Prediction)(NYSE:BRK-B) in the mid-1960s. While the S&P 500 has a cumulative return of about 33,000%…
Tuesday's additional analyst upgrades and downgrades included Carvana, Exxon Mobil, Horizon Therapeutics, Norfolk Southern, Principal Financial, Under Armour and Ventas.
Monday’s top analyst upgrades and downgrades included Applied Materials, Autodesk, BJ's Wholesale Club, Bluebird Bio, Domino’s Pizza, eBay, Foot Locker, Kohl's, Nasdaq, Salesforce, Snowflake, Southern, Teradyne, UDR and ZTO Express.
Warren Buffett's stock portfolio increased by $26.8 billion in the second quarter. Here's how.
Here's a look at how five stocks whose top shareholder is Warren Buffett have performed so far this year.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including CSX, Guess, Snowflake, Zoom Video and more.
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
The current focus on controlling the COVID-19 pandemic, companies that provide other health care products and services have received less attention from investors and analysts. Here are seven that could be winners…
The top analyst upgrades, downgrades and initiations seen on Friday included Alphabet, Amazon.com, Bank of America, Citigroup, Comcast, Intel, Nokia and Starbucks.
These are Warren Buffett's top stock holdings and positions worth noting during the first quarter of 2019.
DaVita Inc. is a major kidney care services company that provides dialysis treatment to patients with end-stage renal disease (ESRD) and chronic kidney disease.
24/7 Wall St.'s 12-month price target for DVA is $212.59, rated Buy. The Wall Street consensus target is $219.86. DVA price prediction →
